Kyverna Therapeutics Inc

Research Kyverna Therapeutics Inc (KYTX) on Bullrun: market cap USD 533.78M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKYTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 533.78M
• Financial periodFY2025
• Net income-USD 161.31M
• Free cash flow-USD 153.72M

Valuation Snapshot

latest market cap is USD 533.78M.

About Kyverna Therapeutics Inc

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.

Frequently asked questions

What is Kyverna Therapeutics Inc's market cap?

Kyverna Therapeutics Inc's market capitalization is USD 533.78M.

What does Kyverna Therapeutics Inc do?

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.